A Phase I Study of AZD0424 Alone and in Combination in Advanced Solid Tumours

PHASE1TerminatedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Advanced Solid Tumours
Interventions
DRUG

AZD0424

"AZD0424 will be administered as a flat dose orally once a day. One treatment cycle consists of 28 days of continuous drug administration with AZD0424, with the flexibility to introduce treatment breaks if required due to cumulative toxicity.~Combination agents and treatment regimen with AZD0424 will be confirmed and approved at a later date."

Trial Locations (3)

Unknown

Belfast City Hospital, Belfast

Edinburgh Cancer Centre - Western General Hospital, Edinburgh

Oxford University Hospitals NHS Trust, Oxford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cancer Research UK

OTHER

NCT01668550 - A Phase I Study of AZD0424 Alone and in Combination in Advanced Solid Tumours | Biotech Hunter | Biotech Hunter